<p>Artificial intelligence (AI)-derived electrocardiographic (ECG) age is a promising marker of atrial fibrillation (AF) risk. We developed PROPHECG-Age Single—an AI model estimating ECG age from wearable single-lead ECGs—and examined whether the ECG-age gap (predicted minus chronological age) is associated with AF presence and burden in real-world self-monitoring context. One million 12-lead ECGs from a hospital were converted to synthetic single-lead signals via Cycle-Consistent Generative Adversarial Network and used to train a residual network-based model. Validation in two independent wearable cohorts (S-Patch [ClinicalTrials.gov: NCT05119725, registered November 2021]; Memo Patch [ClinicalTrials.gov: NCT05355948, registered May 2022]) showed mean absolute errors of 10.01 and 11.88 years, respectively. The pooled association with AF presence was significant (odds ratio 1.03 per 1-year gap), and for AF burden, each 1-year gap increase corresponded to a 0.8 percentage point rise. These findings support wearable-based AI-ECG age as a potential digital biomarker for proactive cardiovascular monitoring.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Wearable device derived electrocardiographic age and its association with atrial fibrillation

  • Seung Hyun Park,
  • Ju Hyun Jin,
  • Jongwoo Kim,
  • Dongha Lee,
  • Daein Kim,
  • Jaeseong Jang,
  • Hee Tae Yu,
  • Seng Chan You,
  • Boyoung Joung

摘要

Artificial intelligence (AI)-derived electrocardiographic (ECG) age is a promising marker of atrial fibrillation (AF) risk. We developed PROPHECG-Age Single—an AI model estimating ECG age from wearable single-lead ECGs—and examined whether the ECG-age gap (predicted minus chronological age) is associated with AF presence and burden in real-world self-monitoring context. One million 12-lead ECGs from a hospital were converted to synthetic single-lead signals via Cycle-Consistent Generative Adversarial Network and used to train a residual network-based model. Validation in two independent wearable cohorts (S-Patch [ClinicalTrials.gov: NCT05119725, registered November 2021]; Memo Patch [ClinicalTrials.gov: NCT05355948, registered May 2022]) showed mean absolute errors of 10.01 and 11.88 years, respectively. The pooled association with AF presence was significant (odds ratio 1.03 per 1-year gap), and for AF burden, each 1-year gap increase corresponded to a 0.8 percentage point rise. These findings support wearable-based AI-ECG age as a potential digital biomarker for proactive cardiovascular monitoring.